- Home
- CIF vs DYAI Comparison
CIF vs DYAI Comparison
Compare CIF & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIF | DYAI |
|---|---|---|
| Founded | 1988 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 32.5M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | CIF | DYAI |
|---|---|---|
| Price | $1.63 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 51.6K | ★ 68.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.65 |
| 52 Week High | $1.82 | $1.35 |
Technical Indicators
Market Signals| Indicator | CIF | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 36.91 |
| Support Level | N/A | N/A |
| Resistance Level | $1.73 | $0.98 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 14.00 |
Price Performance
Historical ComparisonAbout CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.